DRUG
Cetrorelix
0.25 mg subcutaneous injection daily for 6 days
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
Status
Unknown
Phase
Phase 4
Enrollment
150
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Stein and Leventhal were the first to recognize an association between the presence of polycystic ovaries and signs of hirsutism and amenorrhea (eg,oligomenorrhea, obesity), After women diagnosed with Stein-Leventhal syndrome underwent successful wedge resection of the ovaries, their menstrual cycles became regular, and they were able to conceive. As a consequence, a primary ovarian defect was thought to be the main culprit, and the disorder came to be known as polycystic ovarian disease.
Interventions
Treatment arms and agents.
DRUG
Leuprolide Acetate
0.1 mg subcutaneous injection daily for 12 days
Timeline
From registration to results.
First posted
Sep 19, 2019
Study start
Dec 7, 2019
Primary completion
Oct 2020
Study completion
Jan 2021
Results posted
Not reported
Registry updated
Mar 25, 2020
Outcomes
What the study measures.
Primary outcomes
The difference in clinical pregnancy rate in both groups
Time frame · 6 weeks
ultrasound detection of fetal heart pulsations
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 20 Years
- Maximum age
- 35 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: 1. Women under 35 years with polycystic ovary syndrome criteria 2. Normal male semen parameters 3. Normal tubes either by hysterosalpingography \&/or laparoscopy 4. Free from other endocrine abnormalities Exclusion Criteria: 1. NON polycystic ovary syndrome Criteria 2. More than 35 years 3. Abnormal semen parameters 4. Pathological tube\& pelvic factor 5. Other endocrine disorders
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.